An investigation for investors in NASDAQ:ALXN shares over potential securities laws violations by Alexion Pharmaceuticals was announced and NASDAQ:ALXN stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 06/15/2016 --An investigation for investors of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares over potential securities laws violations by Alexion Pharmaceuticals, Inc. in connection certain financial statements was announced.

Investors who purchased shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) concerning whether a series of statements by Alexion Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Alexion Pharmaceuticals, Inc. grew from $88.49 per share in June 2013 to as high as $204.30 per share in July 2015.

On June 6, 2016, Alexion Pharmaceuticals, Inc announced topline results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in patients with refractory generalized myasthenia gravis.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) declined from $155.78 per share on June 6, 2016 to $133.18 per share on June 13, 2016.

Those who purchased shares of Alexion Pharmaceuticals, Inc. have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com